Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Merita is a nutraceutical supplement developed and manufactured by Enactis Healthcare, primarily available in the Indian market. It is formulated as oral capsules containing a combination of 500 mg of tetrahydrocurcuminoids and 5 mg of piperine (95% purity). Tetrahydrocurcuminoids are the primary active metabolites of curcumin, offering superior stability and antioxidant potency compared to the parent compound. They exert anti-inflammatory effects by modulating key signaling pathways, such as the inhibition of cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-κB). Piperine, an alkaloid derived from black pepper, is included to enhance the systemic bioavailability of the curcuminoids by inhibiting metabolic enzymes like CYP3A4 and UDP-glucuronosyltransferases. Merita is marketed for its antioxidant and anti-inflammatory properties, with applications in supporting joint health, digestive function, cardiovascular health, and cognitive performance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Merita.